Galinsky Daliah Shoshana Tamar, Nechushtan Hovav
Oncology Department, Hadassah Hebrew University Medical Center, Hadassah Ein Kerem POB 92000, Jerusalem 91120, Israel.
Crit Rev Oncol Hematol. 2008 Nov;68(2):115-30. doi: 10.1016/j.critrevonc.2008.06.001. Epub 2008 Jul 15.
The incorporation of new anti-cancer kinase inhibitors within cancer management is rapidly increasing. Mast cells are sensitive to several of these new anti-cancer agents most notably to c-Kit inhibitors. As a result, studies investigating the role of mast cells in tumors may have direct clinical relevance and consequently, important clinical implications. Here we review some of the basic attributes of mast cells, especially those related to the new "targeted" drugs. Mast cell roles such as modulators of regulatory T-cells, inducers of angiogenesis and promoters of clot formation are discussed. We also review recent mouse tumor models and human pathological data which implicate mast cells as having both pro- and anti-tumor growth properties. These studies expose a complex, emerging picture of mast cell involvement in tumor biology. It seems that mast cell modulator drugs may improve the efficacy of anti-tumor therapy under certain circumstances, whilst under others, may negatively affect drug efficacy.
新型抗癌激酶抑制剂在癌症治疗中的应用正在迅速增加。肥大细胞对其中几种新型抗癌药物敏感,尤其是对c-Kit抑制剂。因此,研究肥大细胞在肿瘤中的作用可能具有直接的临床相关性,从而具有重要的临床意义。在此,我们综述肥大细胞的一些基本特性,尤其是与新型“靶向”药物相关的特性。讨论了肥大细胞作为调节性T细胞调节剂、血管生成诱导剂和血栓形成促进剂的作用。我们还综述了最近的小鼠肿瘤模型和人类病理数据,这些数据表明肥大细胞具有促进和抑制肿瘤生长的特性。这些研究揭示了肥大细胞参与肿瘤生物学的复杂且新出现的情况。似乎肥大细胞调节剂药物在某些情况下可能提高抗肿瘤治疗的疗效,而在其他情况下可能对药物疗效产生负面影响。